Olmesartan Medoxomil And Amlodipine Clydesdale Pharma (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil and amlodipine is indicated for the management of high blood pressure within the renin‑angiotensin‑aldosterone system and calcium‑channel pathways.

• Hypertension: provides additive blood‑pressure reduction when monotherapy is insufficient.
• Isolated systolic hypertension in the elderly: improves systolic control while maintaining tolerability.
• Hypertensive patients with concomitant peripheral edema from calcium‑channel blockers: amlodipine’s vasodilatory effect is balanced by olmesartan’s arterial relaxation.

• Olmesartan medoxil selectively blocks the AT1 receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Amlodipine inhibits calcium influx into vascular smooth‑muscle cells, producing arterial dilation. The combination yields complementary reductions in systemic vascular resistance and blood pressure.

Both ingredients are generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Peripheral edema: swelling of ankles or feet.
• Dizziness or light‑headedness: especially after the first dose.
• Flushing: transient warmth sensation.
• Fatigue: general tiredness.
• Nausea: occasional upset stomach.

Serious or Rare Side Effects

• Angio‑edema: rapid swelling of face, lips or throat.
• Severe hypotension: marked drop in blood pressure causing faintness.
• Hepatic dysfunction: abnormal liver enzymes.
• Hyperkalemia: elevated potassium levels.
• Renal impairment: worsening kidney function.
• Myocardial infarction: rare but reported in susceptible patients.

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters.

• Renal function: evaluate creatinine clearance and adjust if necessary.
• Hepatic function: check liver enzymes in patients with liver disease.
• Electrolytes: monitor potassium levels, especially if combined with potassium‑sparing agents.
• Pregnancy: avoid use; teratogenic risk is associated with angiotensin‑II blockade.
• Elderly patients: start at lower dose and titrate cautiously.
• Store at ambient temperature: keep below 25°C, retain in original packaging and protect from moisture.

Olmesartan medoxomil and amlodipine may interact with several drug classes; clinicians should review concomitant medications.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of severe hypotension and renal failure.
• Potassium‑sparing diuretics or supplements: may cause hyper‑kalemia.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and affect renal function.
• CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase amlodipine plasma levels.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce amlodipine exposure.
• Lithium: may increase serum lithium concentrations.
• Alcohol: additive hypotensive effect, monitor blood pressure.